Peter Goodhand is a leader in the global health sector as a senior executive and board member.
Goodhand played a key role in the creation of the Global Alliance for Genomics and Health (GA4GH) and was appointed as its founding Executive Director in 2014, and as CEO in 2018. Since May 2016, he has also served as the President of the Ontario Institute for Cancer Research (OICR).
Prior to the GA4GH and OICR, he was the President and CEO of the Canadian Cancer Society, Canada's largest health charity. Before joining the charitable sector, Goodhand had a 20 year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies such as American Cyanamid and Johnson & Johnson; Board Chair and President of Canada’s Medical Device Industry association (MEDEC); and as the founding Managing Director and then Board Chair of the Health Technology Exchange (HTX).
He is currently Chair of the Steering Committee of the Occupational Cancer Research Center, Co-chair of the Medical and Scientific Advisory Board of Global Genes, board member of the AGE-WELL Network Center of Excellence, and on the Steering Committee of the Global Genomic Medicine Collaboration (G2MC).
He chaired the Government of Canada’s Expert working group on the future of medical isotope production, and was a member of the Canadian delegation to the UN summit on non-communicable diseases.